Harley-Davidson has struggled in recent years. Citi says buy the stock

Citi has increased its price target for Kymera Therapeutics (NASDAQ:KYMR) stock to $150, up from $135, while maintaining a Buy rating on the company's shares. The stock is currently trading at $107.39, marking an impressive 85% increase over the past year. However, an InvestingPro tip highlights that the stock's price movements have been rather volatile, with a beta of 1.96.

The firm is particularly excited about Kymera's KT-621 drug, which is set to undergo a Phase 2b trial for atopic dermatitis later this year. Recent data from the Phase 1b study showed a 63% mean improvement in the EASI score at Day 29. Citi believes that a successful outcome could see the drug achieving a placebo-adjusted mean EASI improvement of around 45-50%, with additional benefits like early itch relief and no routine laboratory monitoring needed.

Analysts have been optimistic about Kymera's prospects, setting price targets ranging from $111 to $180, with Citi's new target falling right in the middle of that range. Although the firm has maintained a High Risk rating on the stock, it is clear that there is significant interest and optimism surrounding both Kymera Therapeutics and Axsome Therapeutics as they move forward with their respective drug development initiatives.